

1. Noval Rivas M, Kocatürk B, Franklin BS, Arditi M. Platelets in Kawasaki disease: mediators of vascular inflammation. *Nat Rev Rheumatol*. 2024 Aug;20(8):459-472. doi: 10.1038/s41584-024-01119-3. Epub 2024 Jun 17. PMID:38886559.
2. Machiels JP, Tao Y, Licitra L, Burtneß B, Tahara M, Rischin D, Alves G, Lima PF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. PMID: 38561010.
 Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer. *Heliyon*. 2024 Mar 22;10(7):e28385. doi:10.1016/j.heliyon.2024.e28385. PMID: 38560142; PMCID: PMC10981107.
3. Rizzo A, Rinaldi L, Massafra R, Cusmai A, Guven DC, Forgia D, Latorre A, Giotta F. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. *Future Oncol*. 2024;20(20):1427-1434. doi:10.1080/14796694.2024.2354162. Epub 2024 Jun 12. PMID: 38864297; PMCID: PMC11376414.
4. Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A, Yalcin S, Sahin IH. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review. *Oncologist*. 2024 May 3;29(5):e580-e600. doi:10.1093/oncolo/oyae013. PMID: 38309719; PMCID: PMC11067816.
5. Güven DC, Thong MS, Arndt V. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review. *J Cancer Surviv*. 2024 Jan 4. doi: 10.1007/s11764-023-01507-w. Epub ahead of print. PMID: 38175366.
6. Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. *Cell Death Dis*. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. PMID: 38879508; PMCID: PMC11180193.
7. Laface C, Fina E, Ricci AD, Guven DC, Ambrogio F, De Summa S, Vitale E, Massafra R, Brunetti O, Rizzo A. Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors. *Expert Opin Biol Ther*. 2024 Dec;24(12):1363-1374. doi:10.1080/14712598.2024.2431088. Epub 2024 Nov 18. PMID: 39545466.
8. Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. *Breast Cancer Res Treat*. 2024 Apr;204(2):237-248. doi:10.1007/s10549-023-07165-x. Epub 2023 Dec 19.

PMID: 38112922; PMCID:PMC10948524. doi: 10.1080/1120009X.2024.2330835.
Epub ahead of print. PMID: 38497444.

9. Akyildiz A, Ismayilov R, Rustamova N, Tokatli M, Koc I, Akin S, Kiratli H, Barista I. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management. *Ann Hematol.* 2024 Mar;103(3):905-915. doi: 10.1007/s00277-023-05569-9. Epub 2023 Dec 7. PMID:38057424.
10. Cho BC, Braña I, Cirauqui B, Aksoy S, Couture F, Hong RL, Miller WH Jr, Chaves-Conde M, Teixeira M, Leopold L, Munteanu M, Ge JY, Swaby RF, Hughes BGM. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. *BMC Cancer.* 2024 Jul 25;23(Suppl 1):1254. doi:10.1186/s12885-023-11316-0. PMID: 39054467; PMCID: PMC11270762.
11. Demirci NS, Azizy A, Paksoy N, Doğan İ, Karabulut S, Karahan L, Tastekin D. Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in HER2-negative metastatic gastric cancer patients: A retrospective study. *Medicine (Baltimore).* 2024 Mar 1;103(9):e37259. doi:10.1097/MD.00000000000037259. PMID: 38428877; PMCID: PMC10906642.
12. Guven DC, Stephen B, Sahin TK, Cakir IY, Aksoy S. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. *Laryngoscope.* 2024 Jan;134(1):7-17. doi: 10.1002/lary.30754. Epub 2023 May 25. PMID: 37227161.
13. Parveen M, Karaosmanoglu B, Sucularli C, Uner A, Taskiran EZ, Esendagli G. Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia. *Eur J Immunol.* 2024 May;54(5):e2350717. doi: 10.1002/eji.202350717. Epub 2024 Mar 11. PMID: 38462943.
14. Aksu MD, van der Ent T, Zhang Z, Riza AL, de Nooijer AH, Ricaño-Ponce I, Janssen N, Engel JJ, Streat A, Dijkstra H, Lemmers H, Grondman I, Koeken VACM, Antoniadou E, Antonakos N, van de Veerdonk FL, Li Y, Giamarellos-Bourboulis EJ, Netea MG, Ziogas A. Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis. *J Infect.* 2024 Dec;89(6):106300. doi: 10.1016/j.jinf.2024.106300. Epub 2024 Sep 30. PMID:39357572; PMCID: PMC11624491.
15. Vitale E, Rizzo A, Maistrello L, Guven DC, Massafra R, Mollica V, Monteiro FSM, Santoni M, Massari F. Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis. *Sci Rep.* 2024 Nov 16;14(1):28309. doi:10.1038/s41598-024-71746-z. PMID: 39550353; PMCID: PMC11569249.
16. Majidova N, Aghamaliyeva S, Guliyev M, Dinc G, Akyıldız A, Ozcan E, Akdağ Kahvecioğlu F, Çağrı Yıldırım H, Sever N, Guren AK, Kocaaslan E, Erel P, Agyol Y, Celebi A, Arıkan R, Isık S, Bayoğlu IV, Demirci NS, Dizdar Ö, Hacıbekiroğlu I, Kostek O, Sarı M. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from

Turkey. J Chemother. 2024 Nov 26:1-6. doi:10.1080/1120009X.2024.2430845. Epub ahead of print. PMID: 39588941.